JH-I-25
JH-I-25 is an orally active IRAK1 and IRAK4 inhibitor. JH-I-25 inhibits LPS-induced IRAK4 phosphorylation, IRAK1 degradation, MAPK activation, and the expression of proinflammatory cytokines TNF-α and IL-6 in lung tissues. JH-I-25 improves the survival rate of LPS-induced septic mice and serves as an IRAK4 recruiter in the design of proteolysis-targeting chimeric molecules. JH-I-25 can be used in research related to diffuse large B-cell lymphoma, Waldenström's macroglobulinemia, septic shock, rheumatoid arthritis, atherosclerosis, Alzheimer's disease, acute lung injury, sepsis, and psoriasis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1042673-20-0
- Formule: C20H21N5O3
- Masse moléculaire:379.42
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
|
IRAK1 |
IRAK4 |
IL-6 |
TNF-α |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HBL1 | IC50 |
2.8 μM
Compound: JH-I-25
|
Cytotoxicity against human HBL1 cells assessed as cell growth inhibition measured after 12 days by WST-8 assay
Cytotoxicity against human HBL1 cells assessed as cell growth inhibition measured after 12 days by WST-8 assay
|
[PMID: 34279092] |
In Vitro
JH-I-25 (500 nM; 24 h) inhibits IRAK4 kinase activity and the downstream MAPK signaling pathway in LPS (HY-D1056)-stimulated RAW 264.7 cells, but fails to block the activation of the NF-κB pathway due to its inability to disrupt the scaffolding function of IRAK4[2].
JH-I-25 (pretreatment with 1 μM for 6 h followed by E. coli stimulation for 6 h) reduces the E. coli-induced expression and production of inflammatory cytokines in RAW264.7 cells[3].
JH-I-25 (500 nM; 1 h) inhibits the production of inflammatory cytokines in LPS-stimulated RAW 264.7 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-stimulated RAW 264.7 mouse macrophage cells
-
Concentration:500 nM (pre-incubated for 24 h before 1 h LPS stimulation); 500 nM (pre-incubated for 24 h before LPS stimulation for 0, 15, 30, 60, 120, 180 min)
-
Incubation Time:24 h (pre-incubation before 1 h LPS stimulation); 24 h (pre-incubation before LPS stimulation for 0, 15, 30, 60, 120, 180 min)
-
Result:Effectively inhibited the phosphorylation of IRAK4.
Suppressed LPS-induced IRAK1 degradation.
Blocked phosphorylation of the MAPK pathway components ERK and p38.
Did not block LPS-induced IκB-α degradation, which occurred as early as 15 min in treated cells.
-
Cell Line:LPS-stimulated RAW 264.7 mouse macrophage cells
-
Concentration:500 nM (pre-treated for 1 h before 6 h LPS stimulation)
-
Incubation Time:1 h (pre-treatment before 6 h LPS stimulation)
-
Result:Reduced the transcription of Il6 and Tnfα.
Exhibited a less pronounced inhibitory effect compared to KT-474.
In Vivo
JH-I-25 (20 mg/kg; p.o.; twice daily; administration initiates 12 hours prior to LPS challenge and continues until the end of the experiment) improves the survival rate of C57BL/6 mice in the LPS-induced sepsis model[2].
JH-I-25 (20 mg/kg; p.o.; twice daily; for 6 consecutive days) exerts a protective effect in an imiquimod (HY-B0180)-induced mouse psoriasis model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (~20 g)[2]
-
Dosage:20 mg/kg
-
Administration:i.g.; single dose; 12 hours prior to LPS challenge
-
Result:Reduced LPS-induced TNF-α and IL-6 expression in lung tissues.
Significantly inhibited in vivo MAPK signaling via reduced p-p38 levels.
Did not inhibit IκB-α degradation or NFκB p65 phosphorylation in lung tissue.
Reduced total cell counts in BALF.
Lowered lung wet/dry weight ratio.
Decreased F4/80-positive macrophage accumulation in lung tissue compared to LPS-only mice.
-
Animal Model:C57BL/6[2]
-
Dosage:20 mg/kg
-
Administration:i.g.; twice daily; starting 12 hours prior to LPS challenge and continuing through experimental period
-
Result:Resulted in a significantly higher 7-day survival rate compared to LPS-only sepsis model mice.
-
Animal Model:C57BL/6 (male, daily application of 3.125 mg/mouse imiquimod cream to shaved back skin for 6 days)[3]
-
Dosage:20 mg/kg
-
Administration:p.o.; twice daily; 6 days
-
Result:Improved clinical signs of psoriasis (reduced erythema, scaling, and skin thickness) compared to vehicle-treated controls.
Showed less improvement than LC-MI-3.
Attenuated imiquimod-induced increases in spleen weight.
Had no effect on mouse body weight.
Chemical Information
-
CAS No. 1042673-20-0
-
Masse moléculaire 379.42
-
Formule C20H21N5O3
-
SMILES
O=C(NC1=CC=C(C=C1OC)N2CCOCC2)C3=NC(=CC=C3)C4=NNC=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Pureté et documentation
Références
[1]. Wang L, et al. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). The Journal of biological chemistry. 2019 Mar 22;294(12):4511-4519. [Content Brief]
[3]. Chen L, et al. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases. Journal of medicinal chemistry. 2024 May 23;67(10):8060-8076. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)